NCT05406947Not yet recruiting
Establishment and Clinical Application of Risk Classification Model Based on Molecular Typing of Medulloblastoma in Children
Source: ClinicalTrials.gov · Last updated 8 Feb 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study:(1) Development of a new risk classification model for childhood medulloblastoma. (2) Evaluation and improvement of existing individualized treatment protocols.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 350 (estimated)
- First submitted
- 1 Jun 2022
- Start date
- 30 Jan 2023
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Beijing Tiantan Hospital
- Diseases
- Childhood cancers
- NCT number
- NCT05406947
What you commit to
- Study type: Observational
- Planned participants: 350
- From 30 Jan 2023 to the primary completion date, 31 Dec 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have recently received other drugs or radiation therapy.
Other illness
- Patients suffering from acute or chronic infectious diseases
- Patients suffering from neurological or psychiatric diseases or mental disorders that cannot be easily controlled, or poor compliance.
- Other conditions that the investigator believes make the patient unfit to participate in this trial.
Other
- Patients who cannot receive enhanced MRI scans.
Who the study is looking for
- Age 0.5-18 years (except neonates).
- Pathologically confirmed medulloblastoma.
- Not having received any other relevant treatment before surgery.
- Completion of enhanced MRI of the head and spinal cord.
- Availability of tumor samples and determination of molecular typing.
- Postoperative KPS score ≥ 70.
- Voluntary enrollment in the group and the ability to receive long-term follow-up.
- The patient or the patient's family voluntarily signed the informed consent form.
Age in the registry: 6 months to 18 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.